Many countries have different pricing and reimbursement (P&R) processes for prescription drugs, hospital drugs, medical devices, and procedures. Newer transformational technology classes such as CAR-T, cell- and gene-based therapies may not be classified as drugs and thus may be subject to distinct P&R processes. Indeed, CADTH have announced that it will assess Kymriah® (the first CAR-T cell therapy with marketing authorization in Canada), through its HTA process for medical devices and clinical interventions. CAR-T, cell- and gene-based therapies are classified as advanced therapy medicinal products (ATMPs) in Europe; this research examines how ATMPs have been reimbursed in major European markets.
Authors: Macaulay R, Rothwell S, PAREXEL International, London, United Kingdom
To find out more about this poster you can register to download it here after the ISPOR event.